Medtronic PLC

Medtronic PLC(MDT)股票分析

$94.230

+1.234 (+1.31%)收盤時

Loading chart…
最高
94.720
開盤
93.010
成交量加權均價
93.70
成交量
49.86M
市值
101.72B
最低
92.160
成交金額
4.67B
企業價值/稅息折舊攤銷前利潤(TTM)
13.52

Medtronic Public Limited Company is an Ireland-based company, which provides healthcare technology solutions. The Company’s products category includes Advanced Surgical Technology; Cardiac Rhythm; Cardiovascular; Digestive & Gastrointestinal; Ear, Nose & Throat; General Surgery; Gynecological; Neurological; Oral & Maxillofacial; Patient Monitoring; Renal Care; Respiratory; Spinal & Orthopedic; Surgical Navigation & Imaging; Urological; Product Manuals; Product Ordering & Inquiries; and Product Performance & Advisories. Its products include Cardiac Implantable Electronic Device (CIED) Stabilization, Aortic Stent Graft Products, CareLink Personal Therapy Management Software, CareLink Pro Therapy Management Software. Its services and solutions include Ambulatory Surgery Center Resources, Care Management Services, Digital Connectivity Information Technology (IT) Support, Equipment Services and Support, Innovation Lab, Medtronic Healthcare Consulting, and Office-Based Sinus Surgery.

AI 分析 of Medtronic PLC (MDT)

買進

Medtronic PLC appears to be a good buy at the current price of $88.48, especially given its strong fundamentals and positive catalysts. The company raised its dividend for the 49th consecutive year, indicating a commitment to shareholder returns, and analysts project a revenue growth of 7.25%-7.75% for fiscal 2027. However, the stock has faced challenges, reflected in a 7.88% year-to-date decline. The forward P/E ratio is attractive at 14.93, suggesting potential for upside.

分析師評級(23)

上檔空間 +18.60%
持有
11 買進
12 持有
0 賣出
目前: 94.23
最低
102.00
平均
111.76
最高
120.00

BTIG

2026-10-12

目標價

$99

買進

Barclays

2026-10-06

目標價

$95

Equal Weight

Deutsche Bank

2026-09-03

目標價

$92

持有

UBS

2026-09-03

目標價

$110

買進

Mizuho

2026-09-02

目標價

$115

優於大盤

估值指標

Medtronic PLC(MDT)目前預期本益比為 14.93,5 年平均預期本益比為 16.07。

預期本益比

合理
5 年均值 P/E
16.07
目前P/E
14.93
高估
17.77
低估
14.37

預期 EV/EBITDA

合理
5 年均值 EV/EBITDA
13.66
目前EV/EBITDA
13.52
高估
15.01
低估
12.31

預期股價營收比

低估
5 年均值 P/S
3.43
目前P/S
2.91
高估
3.93
低估
2.94

Alphio AI 對 MDT 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

樂

樂觀

樂觀 · 25%MDT

$89.49

情境價格

基

基準

基準 · 50%MDT

$72.02

情境價格

悲

悲觀

悲觀 · 25%MDT

$70.55

情境價格

持有 MDT 的大戶

R

Renaissance Technologies Corp.

+ 持有MDT

+15.22%

3個月報酬率

E

Edmond de Rothschild Asset Management (France)

+ 持有MDT

+8.72%

3個月報酬率

S

Squarepoint OPS LLC

+ 持有MDT

+8.30%

3個月報酬率

L

LGT Fund Management Company AG

+ 持有MDT

+8.05%

3個月報酬率

A

Arrowstreet Capital, Limited Partnership

+ 持有MDT

+7.99%

3個月報酬率

G

GuideStone Capital Management, LLC

+ 持有MDT

+7.56%

3個月報酬率

事件時間軸

2026-10-13 (ET)

16:00:00

Medtronic Shares Up 0.51% to $92.39

2026-10-12 (ET)

10:00:00

Notable Stock Gains for Medtronic and Others

09:00:00

Medtronic Announces Oversubscribed MiniMed Stock Exchange

2026-10-01 (ET)

16:30:00

AMA Approves New CPT Codes for Medtronic

2026-09-30 (ET)

09:30:00

Medtronic Achieves Regulatory Milestones for Cardiac Ablation Software

資訊

MDT 常見問題 —— 由 Alphio AI 解答

Medtronic Public Limited Company is an Ireland-based company, which provides healthcare technology solutions. The Company’s products category includes Advanced Surgical Technology; Cardiac Rhythm; Cardiovascular; Digestive & Gastrointestinal; Ear, Nose & Throat; General Surgery; Gynecological; Neurological; Oral & Maxillofacial; Patient Monitoring; Renal Care; Respiratory; Spinal & Orthopedic; Surgical Navigation & Imaging; Urological; Product Manuals; Product Ordering & Inquiries; and Product Performance & Advisories. Its products include Cardiac Implantable Electronic Device (CIED) Stabilization, Aortic Stent Graft Products, CareLink Personal Therapy Management Software, CareLink Pro Therapy Management Software. Its services and solutions include Ambulatory Surgery Center Resources, Care Management Services, Digital Connectivity Information Technology (IT) Support, Equipment Services and Support, Innovation Lab, Medtronic Healthcare Consulting, and Office-Based Sinus Surgery. It operates in the Healthcare sector (ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS industry).

Medtronic PLC appears to be a good buy at the current price of $88.48, especially given its strong fundamentals and positive catalysts. The company raised its dividend for the 49th consecutive year, indicating a commitment to shareholder returns, and analysts project a revenue growth of 7.25%-7.75% for fiscal 2027. However, the stock has faced challenges, reflected in a 7.88% year-to-date decline. The forward P/E ratio is attractive at 14.93, suggesting potential for upside.

23 analysts cover MDT: 11 rate it Buy, 12 Hold and 0 Sell. The average price target is 111.76.

暫無貼文

註冊或登入後參與討論

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易